28 January 2020
Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603
Blueberry Therapeutics has received an investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development of BB2603 for the treatment of onychomycosis. The IND is a crucial milestone in the continued development of...
15 January 2020
Blueberry Therapeutics Appoints Dr. Adrian Howd to Board of Directors
Drug discovery and development company Blueberry Therapeutics announced the appointment of Dr. Adrian Howd to its Board as an independent N on- E xecutive D irector , strengthening its strategic, financial and therapeutic expertise . Dr . Howd has over 20 years’ experience...
9 January 2020
Oxford BioTherapeutics Initiates Dose-Escalation Portion of U.S. Phase I Clinical Trial for OBT076 in Patients with Advanced Solid Tumors
Dose-escalation starting at a dose based on results from a European study sponsored by partner, Menarini Ricerche. Phase I program includes two U.S. expansion cohorts: (1) High risk cohort of HER2 negative, Hormone receptor positive (HER2-/HR+) chemotherapy-failure breast...
8 January 2020
Cytox appoints Ian Gilham as new Chairman of the Board
8th January 2020: Oxford & Manchester, UK. Cytox Ltd, which provides non-invasive, risk assessment and patient stratification tools for Alzheimer's disease and dementia, has appointed Dr Ian Gilham as the new Chairman of the Board. Dr Gilham, who brings significant...
12 December 2019
UKI2S, Catapult Ventures and Jonathan Milner invest £500k in Gene Modulation Newcomer Pencil Biosciences
11th December, 2019, Alderley Park: UK Innovation & Science Seed Fund (UKI2S), Catapult Ventures’ GM&C Life Sciences Fund and Jonathan Milner are pleased to announced an investment in Pencil Biosciences, a novel gene modulation company based at Alderley Park...
10 December 2019
AMRC - Dr Peter Jackson article in Laboratory News
Moving from Push to Pull … Nothing less than an entirely new model of drug development is needed if we are to create new antibiotics says Dr Peter Jackson. And it’s something NICE are finally taking seriously as they set about developing a new payment model – good...
19 November 2019
AMR Centre - World Antibiotic Awareness Week
This week is World Antibiotic Awareness Week. Watch the video produced by the AMR Centre here:
12 November 2019
AMR Centre candidate targets superbugs with problem metallo-β-lactamase enzymes
Alderley Park, UK, 11 November 2019 The AMR Centre has nominated a preclinical candidate in its program that tackles drug resistance conferred by NDM-1 and other metallo-β-lactamases (MBL). The MBL inhibitor (MBLI) research program will progress to clinical trials in 2020...
11 November 2019
Nexus Labs selected for prestigious Accelerator Programme at Alderley Park
We are delighted to share that Nexus Labs has been selected for the prestigious A ccelerator Programme at Alderley Park, po wered by BioCity. repres ented by CEO Glyn Estebanez, N exus will be one of 7 high-potential life-sciences start-ups supported by the programme over the...
7 November 2019
Maxwellia's Anna Maxwell nominated for Top 50 Movers & Shakers in BioBusiness 2019
Anna Maxwell, from Catapult portfolio company Maxwellia, has been nominated as a Top 50 Mover & Shaker in BioBusiness 2019. Download the full report here https://bit.ly/34vKLEE